英国全国多中心评估原发性胆汁性胆管炎二线治疗
这项2017年8月至2021年6月的英国全国观察性队列研究纳入457例原发性胆汁性胆管炎患者,349例接受奥贝胆酸(OCA)、108例接受贝特类衍生物治疗。12个月时碱性磷酸酶降幅OCA组29.5%、贝特类组56.7%(P < .001),生化应答率分别为70.6%和80%(P = .121),两组应答率与停药率相似。
要点
- OCA组基线较高风险:碱性磷酸酶更高、肝硬化及胆红素异常比例更大(P < .05)。
- 12个月碱性磷酸酶降幅:OCA组29.5% vs 贝特类组56.7%(P < .001)。
- 12个月生化应答率:OCA组70.6% vs 贝特类组80%(P = .121)。
核心结论
- 在英国原发性胆汁性胆管炎人群中,贝特类衍生物与OCA治疗的生化应答率和停药率相似。
研究设计与样本
- 英国全国观察性队列研究,2017年8月至2021年6月开展。
- 共纳入457例患者,其中349例接受奥贝胆酸(OCA)治疗,108例接受贝特类衍生物(贝扎贝特或非诺贝特)治疗。
主要发现
- 基线时OCA组较贝特类组碱性磷酸酶更高、肝硬化比例更大、胆红素异常比例更高、既往对熊去氧胆酸应答不佳比例更高、弹性成像读数>9.6kPa比例更高(所有P < .05)。
- 完成12个月二线治疗者OCA组259例、贝特类组80例,脱落率分别为25.7%和25.9%。
- 12个月时碱性磷酸酶降幅OCA组29.5% vs 贝特类组56.7%(P < .001)。
- OCA组12个月时血清丙氨酸转氨酶和胆红素正常化比例分别为55.9%和36.4%(P < .001);贝特类组12个月时丙氨酸转氨酶或胆红素正常比例与基线相比无差异。
- 12个月生化应答率OCA组70.6% vs 贝特类组80%(P = .121);倾向评分匹配后及基线高危亚组分析中两组应答率均无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Thirty-to-forty percent of patients with primary biliary cholangitis inadequately respond to ursodeoxycholic acid. Our aim was to assemble national, real-world data on the effectiveness of obeticholic acid (OCA) as a second-line treatment, alongside non-licensed therapy with fibric acid derivatives (bezafibrate or fenofibrate). METHODS: This was a nationwide observational cohort study conducted from August 2017 until June 2021. RESULTS: We accrued data from 457 patients; 349 treated with OCA and 108 with fibric acid derivatives. At baseline/pre-treatment, individuals in the OCA group manifest higher risk features compared with those taking fibric acid derivatives, evidenced by more elevated alkaline phosphatase values, and a larger proportion of individuals with cirrhosis, abnormal bilirubin, prior non-response to ursodeoxycholic acid, and elastography readings >9.6kPa (P < .05 for all). Overall, 259 patients (OCA) and 80 patients (fibric acid derivatives) completed 12 months of second-line therapy, yielding a dropout rate of 25.7% and 25.9%, respectively. At 12 months, the magnitude of alkaline phosphatase reduction was 29.5% and 56.7% in OCA and fibric acid groups (P < .001). Conversely, 55.9% and 36.4% of patients normalized serum alanine transaminase and bilirubin in the OCA group (P < .001). The proportion with normal alanine transaminase or bilirubin values in the fibric acid group was no different at 12 months compared with baseline. Twelve-month biochemical response rates were 70.6% with OCA and 80% under fibric acid treatment (P = .121). Response rates between treatment groups were no different on propensity-score matching or on sub-analysis of high-risk groups defined at baseline. CONCLUSION: Across the population of patients with primary biliary cholangitis in the United Kingdom, rates of biochemical response and drug discontinuation appear similar under fibric acid and OCA treatment.
引用
- Abbas N, Culver EL, Thorburn D, et al. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2022. PMID: 35961518. doi:10.1016/j.cgh.2022.07.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。